Alvogen announced today that it has signed a definitive agreement with Exeltis, a division of the global pharmaceutical group Insud Pharma, to acquire a targeted portfolio of prescription and over-the-counter drugs in the field of women’s healthcare. The transaction includes 23 brands with marketing rights in Russia, Ukraine and Kazakhstan. Majority of the brands acquired will continue to be manufactured by Insud Pharma from their high-quality facilities in Spain and Turkey.
Hacho Hatchikian, Executive Vice President of Alvogen CEE, commented:
“This transaction provides greater scale and diversity across our portfolio and sales channels, while increasing market share in women’s healthcare in key markets. The acquired brands will compliment, as well as significantly strengthen, Alvogen’s existing portfolio in the region.”
About Exeltis: Exeltis is fast growing division of Insud Pharma, an integrated health sciences group. It has developed a leading position in the Women’s Health sector, where it continues to innovate and seek new medicines and devices to improve the health and wellbeing of Women around the world. With a geographical footprint spanning over 40 countries, Exeltis employs over 4,000 professionals supported by a global production network. Exeltis strives to provide care for women throughout their lives. Exeltis offers a broad portfolio of products to respond to patients’ needs in the field of fertility, reproductive health, contraception, pregnancy, birth, and menopause and has expanded its reach in recent years to CNS, Ophthalmology and Endocrinology.